If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

The purpose of this research study is to examine Black women's identity expressions within higher education and how this contributes to their persistence. It further examines how these scholars engage modes of Black finesse to overcome visibility challenges, confront intellectual devaluation, leverage their academic advising relationships, and cultivate joy within these spaces.

Do you live in eastern North Carolina? Do you lack full-time employment with benefits? Do you have paid employment that includes temporary, on-call, gig, or other non-standard employment arrangements? Are you aged 18 to 49? Was there a time in the past 12 months when you felt you needed healthcare but did not receive it? If so, you may be able to participate in a research study to examine the role of work and unmet healthcare needs among precariously-employed adults in eastern North Carolina. Only completion of a survey is needed. Compensation provided.

Would you like to be more active? Are you interested in knowing how it feels to walk inside compared to outside? Join our study to learn about walking on a treadmill and walking outside. By joining, you may help us learn more about body shape and size. No need to worry, we will guide you through everything! You can earn money for participating.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.

Are you an Iranian woman between 35-50 living in the U.S.? Share your story about how social media affects your sense of identity, connection, and community. Your voice matters.

Have you been recently diagnosed with T1D? You may be able to participate in a research study for an investigational cell therapy product to see if it is safe for patients with T1D and to see if it helps to slow down the progression of T1D.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.

The standard treatment for newly-diagnosed multiple myeloma (NDMM) is autologous stem cell transplantation (ASCT). For this procedure, a patient's own healthy, blood-forming cells are collected. The patient then receives high-dose chemotherapy or radiation to kill the cancer cells. Then their healthy cells are returned to their body to recover. While ASCT is effective for many patients, it has significant side effects and may not be the best option for every patient with NDMM. In this research study, participants will receive one of two (2) study treatments: a new regimen of elranatamab plus daratumumab or a conventional regimen of ASCT plus lenalidomide and daratumumab. The delayed use of ASCT, as explored in this research study, is experimental and not standard-of-care.